Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies.

The experts

• Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
• Dr Jean-Phillippe Metges, Brest University Hospital, Brest, France
• Dr Radka Obermannova, Masaryk Memorial Cancer Institute Brno, Czech Republic

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncologyime.org/targeting-pathobio-of-ESCC-and-emerging-impact-of-IO